TrialAnnals of hematology2019

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.

Anthony S Stein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.